Four IPOs to Watch That Aren't Facebook

By MoneyShow.com Feb 09, 2012 11:15 am

With all the talk about Facebook filing for a stock offering, all the other interesting IPO stories have been drowned out. And the number of IPOs -- outside of the tech sector, no less -- is impressive.



Facebook’s IPO is attracting all the headlines, but the social network’s much-anticipated stock debut won’t actually happen until May. Meanwhile, nine smaller companies are scheduled to hit the market this week, injecting life into an IPO market that was virtually stagnant in January.

Just four companies went public in January. But February opened with a bang, as four more IPOs debuted in the first two days of the month alone. That was only prelude to the nine that will debut this week — the busiest week of IPOs since mid-December.

Here are a few of the headliners from this week’s crowded IPO lineup:

1. Caesars Entertainment (CZR)
This Las Vegas-based casino chain kicked off the busy week with an initial public offering in which the company raised a little over $16 million.

It could use the money. Caesars is sitting on a pile of debt — $22 billion to be exact. The company made a small dent in its debt load by offering 1.81 million shares at $9 a pop.

Considering the massive debt and that the company’s previous attempt to go public failed in 2010, Caesars’ IPO is a massive gamble for investors.

2. Cementos Pacasmayo SAA (CPAC)
The most ambitious IPO of the week raised $230 million by offering 20 million shares at $11.50 a share.

Cementos is a Peruvian producer and distributor of (you guessed it) cement. The company was founded in 1949 and booked $349 million in sales over the last 12 months. That makes Cementos the second-largest cement company in Peru.

3. ChemoCentryx (CCXI)
This California-based company purports to be the developer of novel drugs that will treat Crohn’s disease and rheumatoid arthritis. The company planned to raise $60 million by offering 4 million shares at a price range of $14 to $16, but then cut its price to $10 at the last minute.

As a biopharmaceutical company, ChemoCentryx faces plenty of competition from the likes of Johnson & Johnson (JNJ), Pfizer (PFE), and Amgen (AMGN).

4. Roundy’s (RNDY)
If you live in Illinois, Minnesota, or Wisconsin, you know this company. Roundy’s is a Midwest supermarket chain with 158 stores across those three states. The company raised about $150 million by offering 18.2 million shares at $8.50.

Roundy’s has plenty of history: It was founded in 1872. However, the company is saddled with debt, and revenue has been essentially flat over the last three years.

To become more appealing to investors, Roundy’s plans to offer a very generous dividend yield of 8.4 annually. That may be enough to entice short-term investors, but it will be difficult for a small company with a pile of debt to sustain over the long term.

Editor's Note: This article was written by Chris Preston of The Daily Profit.

Below, find some more great investing and trading content from MoneyShow:


Growth Buzz Is Strong for 7 Energy Picks
By Greg Group

UK Fashion Brand Losing Its Chic
By Cliff D'Arcy

'Secret' Metric Unearths 5 Stock Gems
By Carla Pasternak

5 Medical Stocks With Healthy Charts
By Kate Stalter


Twitter: @TopProsTopPicks
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
  • All the News and Insights You Need Right in Your Inbox | Sign Up for Our Free Newsletter

WHAT'S POPULAR IN THE VILLE

Recommendations

MARKETS